ASCO 2020

Complete Coverage

KEYNOTE-604: Pembrolizumab Missed OS Endpoint in First-Line SCLC, but Appeared to Prolong Survival in Some Patients

The drug did, however, significantly improve progression-free survival.

Bispecific DART Molecule Targeting PD-1, LAG3 Active, Well-Tolerated

Encouraging activity noted in several tumor types.

KEYNOTE-100: Pembrolizumab Had Modest Activity in Recurrent Advanced Ovarian Cancer

Analysis of biomarkers to predict response to pembrolizumab are ongoing.

Tyrer-Cuzick Breast Cancer Model Well-Calibrated Among Most Races/Ethnicities

The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.

Olaparib/Cediranib Combination Is Not Superior to Standard of Care in Recurrent Ovarian Cancer

Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.

Secondary Cytoreductive Surgery Extended PFS in Recurrent Ovarian Cancer

A longer treatment-free survival interval associated with surgery may contribute to overall survival.

Birth Rates After ART Not Significantly Different Among Female Cancer Survivors, Siblings

The researchers found that patients who received pelvic radiation had a decreased chance of live birth.

Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers

A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.

Lenvatinib, Pembrolizumab Combination Promising in Unresectable HCC

The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.

Circulating Tumor DNA Levels Linked with Tumor Burden, Survival in HCC

Noninvasive method could help monitor treatment responses.

Comparing Stereotactic Body Radiation Therapy With Transarterial Chemoembolization in Early-Stage HCC

SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.

Apatinib Significantly Improved Survival in Chinese Patients with Advanced HCC

The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.

Intrahepatic T-VEC Injection Plus Pembrolizumab Feasible in HCC, Liver Metastases

Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.

Researchers Present Evidence in Support of Broad Next-Generation Sequencing in Advanced Nonsquamous NSCLC

Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.

Bintrafusp Alfa: Durable Responses Noted in NSCLC

In the 3 ongoing responses, all had PD-L1–positive disease.

Worse Outcomes With Irinotecan and Temolozomide in Ewing Sarcoma

Irinotecan and temozolomide led to inferior clinical outcomes for patients with recurrent and primary refractory Ewing sarcoma, a multiarm trial found.

Nivolumab Plus Ipilimumab Yields Long-Term Responses in Advanced NSCLC

Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.

Standard Chemotherapy Regimen in US Improved Outcomes in Ewing Sarcoma

A chemotherapy regimen that is standard in the US for patients with Ewing sarcoma appeared to improve outcomes, a randomized phase 3 trial showed.

Pralsetinib Appears Promising in RET Fusion-Positive NSCLC

Three of 9 patients with measurable central nervous system metastases had an intracranial complete response, with a 56% overall response rate in this subgroup.

HER2-Positive NSCLC: Trastuzumab Deruxtecan Shows Promising Activity

Twenty-six (61.9%) patients had an ORR as confirmed by independent central review.